Premium
Colocalization of phosphorylated forms of WAVE1, CRMP2, and tau in Alzheimer's disease model mice: Involvement of Cdk5 phosphorylation and the effect of ATRA treatment
Author(s) -
Watamura Naoto,
Toba Junya,
Yoshii Aya,
Nikkuni Miyu,
Ohshima Toshio
Publication year - 2016
Publication title -
journal of neuroscience research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.72
H-Index - 160
eISSN - 1097-4547
pISSN - 0360-4012
DOI - 10.1002/jnr.23674
Subject(s) - colocalization , cyclin dependent kinase 5 , phosphorylation , tau protein , tauopathy , kinase , gsk 3 , medicine , chemistry , endocrinology , alzheimer's disease , biology , microbiology and biotechnology , biochemistry , protein kinase a , neurodegeneration , disease , cyclin dependent kinase 2
Alzheimer's disease (AD) is the most common type of dementia among the elderly. Neurofibrillary tangles (NFTs), a major pathological hallmark of AD, are composed of tau protein that is hyperphosphorylated by cyclin‐dependent kinase 5 (Cdk5) and glycogen synthase kinase 3β (GSK3β). NFTs also contain Wiskott‐Aldrich syndrome protein family verprolin‐homologous protein 1 (WAVE1) and collapsin response‐mediator protein 2 (CRMP2). Although Cdk5 is known to phosphorylate tau, WAVE1, and CRMP2, the significance of this with respect to NFT formation remains to be elucidated. This study examines the involvement of phosphorylated (p‐) CRMP2 and WAVE1 in p‐tau aggregates using a triple‐transgenic (3×Tg; APPswe/PS1M146V/tauP301L) AD mouse model. First, we verified the colocalization of p‐WAVE1 and p‐CRMP2 with aggregated hyperphosphorylated tau in the hippocampus at 23 months of age. Biochemical analysis revealed the inclusion of p‐WAVE1, p‐CRMP2, and tau in the sarkosyl‐insoluble fractions of hippocampal homogenates. To test the significance of phosphorylation of these proteins further, we administered all‐trans‐retinoic acid (ATRA) to the 3×Tg mice, which downregulates Cdk5 and GSK3β activity. In ATRA‐treated mice, fewer and smaller tau aggregates were observed compared with non‐ATRA‐treated mice. These results suggest the possibility of novel therapeutic target molecules for preventing tau pathology. © 2015 Wiley Periodicals, Inc.